Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: Performance in the UK NEQAS proficiency testing programme

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 12, 2004, Pages 2178-2184

  Jennings, Ian ^a   Mackie, I ^b   Arnout, J ^c   Preston, F E ^a  

^a UK NEQAS for Blood Coagulation   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Lupus anticoagulant; Monoclonal antibodies; Quality control

Indexed keywords

BETA2 GLYCOPROTEIN 1; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PROTHROMBIN;

ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; HEMOSTASIS; HUMAN; LABORATORY DIAGNOSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; QUALITY CONTROL; SCREENING TEST; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM;

ALGORITHMS; ANTIBODIES, MONOCLONAL; BETA 2-GLYCOPROTEIN I; BLOOD COAGULATION TESTS; GLYCOPROTEINS; GREAT BRITAIN; HUMANS; LABORATORIES; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; THROMBOPLASTIN; TIME FACTORS; WHOLE BLOOD COAGULATION TIME;

EID: 13244292384     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01028.x     Document Type: Article

References (20)

1. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531-6.
2. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic Inputs erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
3. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
4. Galli M, Dlott J, Norbis F, Ruggeri L, Cler L, Triplett DA, Barbui T. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost 2000; 84: 1012-6.
5. Jennings I, Kitchen S, Woods TAL, Preston FE, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK NEQAS for Blood Coagulation. Thromb Haemost 1997; 77: 934-7.
6. Roussi J, Roisin JP, Goguel A. Lupus anticoagulants: First French Interlaboratory Etalanorme Survey. Am J Clin Pathol 1996; 105: 788-93.
7. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119: 364-9.
8. Ichikawa K, Suzuki T, Hashimoto Y, Sumida T, Tomioka H, Yoshida S, Koike T. Monoclonal autoantibodies to cardiolipin derived from SLE mice. Lupus 1992; 1: 239-47.
9. Takeya H, Mori T, Gabazza EC, Kuroda K, Deguchi H, Matsuura E, Ichikawa K, Koike T, Suzuki K. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. J Clin Invest 1997; 99: 2260-8.
10. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe. an analysis of results from the tirst European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human β2-glycoprotein 1. Thromb Haemost 1999; 81: 929-34.
11. Kitchen S, Walker ID, Woods TAL, Preston FE on behalf of the Steering Committee of the UK NEQAS in Blood Coagulation. Thromboplastin related differences in the determination of international normalised ratio: a cause for concern? Thromb Haemost 1994; 72: 426-9.
12. Exner T, Rickard KA, Kronenberg H. A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. Br J Haematol 1978; 40: 143-51.
13. Greaves M, Cohen H, MacHin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15.
14. Medical Devices Agency. Evaluation of Lupus Anticoagulant Kits. MDA/98/48 1998. London, UK; Department of Health; 1998.
15. Ames PR, Iannaccone L, De Iasio R, Brancaccio V. Improved confirmation of weak lupus anticoagulants by employing sensitive and insensitive reagents to the lupus anticoagulant. Blood Coagul Fibrinolysis 2001; 12: 563-7.
16. Arnout J, Vanrusselt M, Wittevrongel C, Vermylen J. Monoclonal antibodies against beta-2-glycoprotein I. use as reference material for lupus anticoagulant tests. Thromb Haemost 1998; 79 955-8.
17. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003; 49: 1608-14.
18. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
19. Le Querrec A, Arnout J, Arnoux D, Borg JY, Caron C, Darnige L, Delahousse B, Reber G, Sie P. Quantification of lupus anticoagulants in clinical samples using anti-β2GP1 and anti-prothrombin monoclonal antibodies. Thromb Haemost 2001; 86: 584-9.
20. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-9.